Skip to content

Author

A. Langhoff

8 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Abstract 16691: High-Dose versus Standard-Dose Influenza Vaccine in Older Adults with Neurological and Cerebrovascular Disease: A Prespecified Analysis of the DANFLU-2 Trial

Background: Adults with neurological or cerebrovascular (NeCVD) disease have an elevated risk of influenza-related complications. Whether HD-IIV provides greater relative benefit over SD-IIV in this population is uncertain. Objective: To evaluate the relative vaccine effectiveness (rVE) of high-dose inactivate...

M. Yafasov, N. Johansen, D. Modin et al. · 0 citations
Open access Oct 2026

Early magnesium changes may contribute to SGLT2 inhibitor–induced left ventricular mass regression in CKD

Disturbances in the bone and mineral homeostasis are central drivers of cardiovascular disease in chronic kidney disease (CKD), contributing to vascular calcification and left ventricular hypertrophy. In DECODE-CKD, the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin induced significant left ventr...

K. Bartholdy, N. Johansen, D. Modin et al. · 0 citations
Oct 2026

Effect of Colchicine on Arterial Stiffness in Patients With Hypertension: The COlchicine HypERtENsion Trial (COHERENT).

AIM This trial investigated whether colchicine, an anti-inflammatory treatment, affects cardiovascular structure and function, assessed by arterial stiffness, blood pressure and biochemistry, compared with placebo. METHODS COHERENT was a randomized, double-blind, placebo-controlled trial of the effects of colchicine...

A. Langhoff, N. Johansen, K. Bartholdy et al. · 0 citations
Open access Oct 2026

Effects of colchicine on cardiac structure and function in patients with hypertension: a prespecified secondary analysis of the COlchicine HypERtENsion Trial (COHERENT)

Hypertension is a common and important risk factor for cardiovascular (CV) disease. The immune system and inflammatory response contribute to the pathology of hypertension. Colchicine has shown promise in delaying the progression of manifest atherosclerotic disease. However, the effects of colchicine on cardiac s...

A. Langhoff, N. Johansen, K. Bartholdy et al. · 0 citations
Aug 2026

Bivalent RSV Prefusion F Vaccine to Prevent Hospitalizations in Adults.

BACKGROUND Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease in adults, with the highest burden among older adults and individuals with chronic health conditions. The bivalent RSV prefusion F (RSVpreF) vaccine has been shown to prevent RSV-associated respiratory illness, but data fro...

M. Lassen, S. Christensen, M. Yafasov et al. · 1 citation
Open access 2027

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty...

C. Espersen, N. Johansen, D. Modin et al. · 0 citations
Open access Sep 2026

Sex differences in acute heart failure: clinical presentation, imaging findings, and short-term recovery

Abstract Introduction Sex differences in chronic heart failure are well established, but corresponding differences in acute heart failure (AHF), particularly in multimodal imaging findings and short-term recovery, remain incompletely characterized. Methods In this prospective observational study, 567 adults hospitalize...

A. Khoraizat, F. Davidovski, C. Espersen et al. · 0 citations
Open access Sep 2026

Cardiac Structure and Function and Pulmonary Congestion Across New York Heart Association Classes in Patients With Acute Heart Failure

Acute heart failure (AHF) is a major global health challenge, yet the relationship between New York Heart Association (NYHA) classification and objective markers such as echocardiography, lung ultrasound (LUS), and biomarkers remains unclear.

A. Al-Rubai, F. Davidovski, C. Espersen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.